{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T02:45:30Z","timestamp":1771987530219,"version":"3.50.1"},"reference-count":194,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T00:00:00Z","timestamp":1543363200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01357","type":"journal-article","created":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T05:10:01Z","timestamp":1543381801000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Daniel","family":"Heudobler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rechenmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"L\u00fcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Vogelhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Klobuch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Pukrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Hackl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ghibelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Reichle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-a and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11912-017-0594-5","article-title":"Adjuvant therapy for melanoma","volume":"19","author":"Agha","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1073\/pnas.0910668107","article-title":"8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC","volume":"107","author":"Ahmadiyeh","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B4","first-page":"59","article-title":"The genomic landscape characterizing metastasis","author":"Allgayer","year":"2018","journal-title":"Cancer Microenviron."},{"key":"B5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nrd2397","article-title":"RAR and RXR modulation in cancer and metabolic disease","volume":"6","author":"Altucci","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.trecan.2017.03.011","article-title":"Metronomic chemotherapy: direct targeting of cancer cells after all?","volume":"3","author":"Andr\u00e9","year":"2017","journal-title":"Trends Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1158\/1078-0432.CCR-07-4274","article-title":"Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer","volume":"14","author":"Attia","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1179\/1607845415Y.0000000002","article-title":"Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory\/relapsed cutaneous T-cell lymphoma","volume":"20","author":"Aviles","year":"2015","journal-title":"Hematology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nature25193","article-title":"A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies","volume":"553","author":"Bahr","year":"2018","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1200\/JCO.1997.15.8.2945","article-title":"Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival\u2013a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years","volume":"15","author":"Bastion","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijrobp.2015.09.040","article-title":"Phase 2 randomized controlled trial of radiation therapy plus concurrent interferon-alpha and retinoic acid versus cisplatin for stage III cervical carcinoma","volume":"94","author":"Basu","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B13","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nature10275","article-title":"A continuum model for tumour suppression","volume":"476","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","article-title":"Drug repurposing in oncology\u2013patient and health systems opportunities","volume":"12","author":"Bertolini","year":"2015","journal-title":"Nat. Revi. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/path.4723","article-title":"Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy","volume":"239","author":"Beyar-Katz","year":"2016","journal-title":"J. Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/550188a","article-title":"Cancer care: Tap latent source of frugal cancer ideas","volume":"550","author":"Bouche","year":"2017","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/ncb3625","article-title":"Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche","volume":"19","author":"Boyd","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","article-title":"Transcriptional Addiction in Cancer","volume":"168","author":"Bradner","year":"2017","journal-title":"Cell"},{"key":"B24","first-page":"115","article-title":"Retinoids, cisplatin and interferon-\u03b1 in recurrent or metastatic cervical squamous cell carcinoma: clinical results of 2 phase II trials","volume":"13","author":"Braud","year":"2002","journal-title":"European Cytokine Netw."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.1995.13.9.2354","article-title":"Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group","volume":"13","author":"Browman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1200\/JCO.1995.13.10.2679","article-title":"Response to 13-cis-retinoic acid plus interferon alfa-2a in two patients with therapy-refractory advanced renal cell carcinoma","volume":"13","author":"Buer","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1024038127156","article-title":"Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study","volume":"79","author":"Burstein","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1158\/1078-0432.CCR-16-0238","article-title":"Immunomodulatory effect of vitamin D after allogeneic stem cell transplantation: results of a prospective multicenter clinical trial","volume":"22","author":"Caballero-Vel\u00e1zquez","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1745-7254.2007.00571.x","article-title":"Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells","volume":"28","author":"Cao","year":"2007","journal-title":"Acta Pharmacol. Sin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","article-title":"Repurposing metformin for cancer treatment: current clinical studies","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1080\/10428190902748971","article-title":"Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma","volume":"50","author":"Chanan-Khan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","first-page":"djv350","DOI":"10.1093\/jnci\/djv350","article-title":"Continuous combined estrogen plus progestin and endometrial cancer: the women's health initiative randomized trial","volume":"108","author":"Chlebowski","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"B33","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1158\/0008-5472.CAN-16-3130","article-title":"Pharmacokinetics and pharmacodynamics-based mathematical modeling identifies an optimal protocol for metronomic chemotherapy","volume":"77","author":"Ciccolini","year":"2017","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/leu.2016.122","article-title":"PML-RAR\u03b1 kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy","volume":"30","author":"Cicconi","year":"2016","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1158\/0008-5472.CAN-05-2726","article-title":"Sequential valproic acid\/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia","volume":"66","author":"Cimino","year":"2006","journal-title":"Cancer Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1200\/JCO.2008.20.7944","article-title":"Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma","volume":"27","author":"Clarke","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/archderm.140.12.1504","article-title":"Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma","volume":"140","author":"Coras","year":"2004","journal-title":"Arch. Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/sj.bjc.6601306","article-title":"A phase II trial with rosiglitazone in liposarcoma patients","volume":"89","author":"Debrock","year":"2003","journal-title":"Br. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1073\/pnas.96.7.3951","article-title":"Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-\u03b3 ligand troglitazone in patients with liposarcoma","volume":"96","author":"Demetri","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","article-title":"Retinoic acid receptors: from molecular mechanisms to cancer therapy","volume":"41","author":"Di Masi","year":"2015","journal-title":"Mol. Aspects Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cytogfr.2014.11.008","article-title":"The use of interferon in melanoma patients: a systematic review","volume":"26","author":"Di Trolio","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"New Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.urology.2003.08.041","article-title":"Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study","volume":"63","author":"Dimopoulos","year":"2004","journal-title":"Urology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.3109\/10428194.2012.656625","article-title":"Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor\/retinoid X receptor activation by histone deacetylase inhibition","volume":"53","author":"Dummer","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-14-0209","article-title":"Tumors: wounds that do not heal-redux","volume":"3","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mce.2009.10.013","article-title":"The role of the PAX8\/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer","volume":"321","author":"Eberhardt","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2016.71.3743","article-title":"Phase III randomized, placebo-controlled, double-blind trial of celecoxib in addition to standard chemotherapy for advanced non-small-cell lung cancer with cyclooxygenase-2 overexpression: CALGB 30801 (Alliance)","volume":"35","author":"Edelman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","article-title":"Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes","volume":"32","author":"Efficace","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"704165","DOI":"10.1155\/2008\/704165","article-title":"PPARgamma and apoptosis in cancer","volume":"2008","author":"Elrod","year":"2008","journal-title":"PPAR Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/dom.12608","article-title":"Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes","volume":"18","author":"Erdmann","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2013the International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"Faiss","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/annonc\/mdl144","article-title":"Interferon-\u03b1 and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?","volume":"18","author":"Fazio","year":"2007","journal-title":"Ann. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Revi. Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2217\/imt.13.108","article-title":"Epigenetics of melanoma: implications for immune-based therapies","volume":"5","author":"Fratta","year":"2013","journal-title":"Immunotherapy"},{"key":"B65","doi-asserted-by":"publisher","first-page":"845340","DOI":"10.1155\/2015\/845340","article-title":"Chemotherapy and chemoprevention by thiazolidinediones","volume":"2015","author":"Fr\u00f6hlich","year":"2015","journal-title":"Biomed Res. Int."},{"key":"B66","first-page":"29","article-title":"From cutaneous metastasis tob rain metastasis: proteome signatures and functional features of melanoma cells","author":"Gerner","year":"2018","journal-title":"Cancer Microenviron."},{"key":"B67","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2741\/3849","article-title":"Targeting rapid action of sex-steroid receptors in breast and prostate cancers","volume":"4","author":"Giovannelli","year":"2012","journal-title":"Front. Biosci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1002\/cncr.10809","article-title":"Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma","volume":"95","author":"Goldberg","year":"2002","journal-title":"Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12032-016-0759-3","article-title":"Targeting persistent androgen receptor signaling in castration-resistant prostate cancer","volume":"33","author":"Graham","year":"2016","journal-title":"Med. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1111\/jdv.13391","article-title":"Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial","volume":"30","author":"Hart","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12307-015-0170-1","article-title":"Anakoinosis: Communicative reprogramming of tumor systems - for rescuing from chemorefractory neoplasia","volume":"8","author":"Hart","year":"2015","journal-title":"Cancer Microenviron."},{"key":"B72","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000120028","article-title":"Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas-a phase II study","volume":"73","author":"Hau","year":"2007","journal-title":"Oncology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1007\/s00432-015-1963-9","article-title":"Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma","volume":"141","author":"Herold","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3389\/fphar.2018.01279","article-title":"Cutaneous leukemic infiltrates successfully treated with biomodulatory therapy in a rare case of therapy-related high risk MDS\/AML","volume":"9","author":"Heudobler","year":"","journal-title":"Front. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"E3540","DOI":"10.3390\/ijms19113540","article-title":"Peroxisome proliferator-activated receptors (PPAR)\u03b3 agonists as master modulators of tumor tissue","volume":"19","author":"Heudobler","year":"","journal-title":"Int. J. Mol. Sci."},{"key":"B76","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood.V128.22.4254.4254","article-title":"Biomodulatory metronomic therapy shows remarkable activity in chemorefractory multi-system langerhans cell histiocytosis","volume":"128","author":"Heudobler","year":"2016","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(15)00565-3","article-title":"Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial","volume":"17","author":"Higurashi","year":"2016","journal-title":"Lancet Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1200\/JCO.1995.13.6.1297","article-title":"Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer","volume":"13","author":"Hill","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","article-title":"Super-enhancers in the control of cell identity and disease","volume":"155","author":"Hnisz","year":"2013","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molcel.2015.02.014","article-title":"Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers","volume":"58","author":"Hnisz","year":"2015","journal-title":"Mol. Cell"},{"key":"B81","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41467-018-03279-9","article-title":"Dissecting super-enhancer hierarchy based on chromatin interactions","volume":"9","author":"Huang","year":"2018","journal-title":"Nat. Commun."},{"key":"B82","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s11864-012-0223-3","article-title":"Role of arsenic trioxide in acute promyelocytic leukemia","volume":"14","author":"Iland","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1158\/1078-0432.CCR-06-2316","article-title":"WNT signaling pathway and stem cell signaling network","volume":"13","author":"Katoh","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.canlet.2017.02.005","article-title":"The potential clinical promise of \u2018multimodality\u2019 metronomic chemotherapy revealed by preclinical studies of metastatic disease","volume":"400","author":"Kerbel","year":"2017","journal-title":"Cancer Lett."},{"key":"B87","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.seminhematol.2015.04.003","article-title":"Epigenetic therapy in acute myeloid leukemia: current and future directions","volume":"52","author":"Kim","year":"2015","journal-title":"Semin. Hematol."},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01380","article-title":"Biomodulatory treatment with azacitidine, all-trans retinoic acid and pioglitazone induces differentiation of primary AML blasts into neutrophil like cells capable of ROS production and phagocytosis","author":"Klobuch","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1517\/13543784.15.7.795","article-title":"Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach","volume":"15","author":"Koutsilieris","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.ophtha.2012.03.045","article-title":"Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up","volume":"119","author":"Krilis","year":"2012","journal-title":"Ophthalmology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/00130404-200209000-00010","article-title":"A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer","volume":"8","author":"Kulke","year":"2002","journal-title":"Cancer J."},{"key":"B93","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10637-016-0335-x","article-title":"Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer","volume":"34","author":"Kummar","year":"2016","journal-title":"Invest. New Drugs"},{"key":"B94","doi-asserted-by":"publisher","first-page":"5879090","DOI":"10.1155\/2017\/5879090","article-title":"Interactions between PPAR gamma and the canonical Wnt\/Beta-catenin pathway in Type 2 diabetes and colon cancer","volume":"2017","author":"Lecarpentier","year":"2017","journal-title":"PPAR Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000227450","article-title":"Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors","volume":"52","author":"Lissoni","year":"1995","journal-title":"Oncology"},{"key":"B96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1023\/A:1010619225209","article-title":"High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy","volume":"67","author":"L\u00f8nning","year":"2001","journal-title":"Breast Cancer Res. Treat."},{"key":"B98","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature25169","article-title":"Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling","volume":"553","author":"Mack","year":"2018","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00002371-200003000-00011","article-title":"Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer","volume":"23","author":"Mantovani","year":"2000","journal-title":"J. Immunother."},{"key":"B100","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood.V96.9.3188","article-title":"Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist","volume":"96","author":"Masood","year":"2000","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1074\/mcp.RA117.000425","article-title":"Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia","volume":"17","author":"Mayer","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"B102","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"848645","DOI":"10.1155\/2010\/848645","article-title":"Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma","volume":"2009","author":"Meyer","year":"2009","journal-title":"PPAR Res."},{"key":"B106","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.1997.15.2.790","article-title":"Initial clinical trial of a selective retinoid X receptor ligand, LGD1069","volume":"15","author":"Miller","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B107","first-page":"471","article-title":"Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid","volume":"2","author":"Miller","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br. J. Haematol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New Engl. J. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"10990","DOI":"10.1073\/pnas.180329197","article-title":"Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer","volume":"97","author":"Mueller","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B111","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1210\/er.2003-0034","article-title":"Interaction of nuclear receptors with the Wnt\/beta-catenin\/Tcf signaling axis: Wnt you like to know?","volume":"26","author":"Mulholland","year":"2005","journal-title":"Endocr. Rev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1074\/mcp.M116.063313","article-title":"Multi-omics analysis of serum samples demonstrates reprogramming of organ functions via systemic calcium mobilization and platelet activation in metastatic melanoma","volume":"16","author":"Muqaku","year":"2017","journal-title":"Mol. Cell. Proteomics"},{"key":"B113","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","article-title":"Epigenetic treatment of solid tumours: a review of clinical trials","volume":"7","author":"Nervi","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/1389450117666160201114752","article-title":"Immunotherapy and hormone-therapy in metastatic breast cancer: a review and an update","volume":"17","author":"Nicolini","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"B116","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/cbr.2006.365","article-title":"Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status","volume":"22","author":"Norsa","year":"2007","journal-title":"Cancer Biother. Radiopharm."},{"key":"B117","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ctrv.2017.02.005","article-title":"Ovarian ablation for premenopausal breast cancer: a review of treatment considerations and the impact of premature menopause","volume":"55","author":"Nourmoussavi","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"9456020","DOI":"10.1155\/2017\/9456020","article-title":"Crosstalk between the Androgen receptor and PPAR gamma signaling pathways in the prostate","volume":"2017","author":"Olokpa","year":"2017","journal-title":"PPAR Res."},{"key":"B119","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1593\/neo.07871","article-title":"Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response","volume":"10","author":"Pahler","year":"2008","journal-title":"Neoplasia"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/cdd.2011.207","article-title":"Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells","volume":"19","author":"Papi","year":"2012","journal-title":"Cell Death Differ."},{"key":"B121","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2010.04.026","article-title":"RXRgamma and PPARgamma ligands in combination to inhibit proliferation and invasiveness in colon cancer cells","volume":"297","author":"Papi","year":"2010","journal-title":"Cancer Lett."},{"key":"B122","doi-asserted-by":"publisher","first-page":"e54968","DOI":"10.1371\/journal.pone.0054968","article-title":"Peroxisome proliferator activated receptor-\u03b1\/hypoxia inducible factor-1\u03b1 interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells","volume":"8","author":"Papi","year":"2013","journal-title":"PLoS ONE"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1111\/j.1471-4159.2009.06111.x","article-title":"PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models","volume":"109","author":"Papi","year":"2009","journal-title":"J. Neurochem."},{"key":"B124","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","article-title":"Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study","volume":"6","author":"Pasquier","year":"2016","journal-title":"EBioMedicine"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1158\/0008-5472.CAN-11-0568","article-title":"Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression","volume":"71","author":"Pitteri","year":"2011","journal-title":"Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1016\/j.juro.2007.01.119","article-title":"Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer","volume":"177","author":"Pomerantz","year":"2007","journal-title":"J. Urol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamaoncol.2017.0324","article-title":"Metronomic chemotherapy vs best supportive care in progressive pediatric solid malignant tumors: a randomized clinical trial","volume":"3","author":"Pramanik","year":"2017","journal-title":"JAMA Oncol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPAR\u03b3 agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"B130","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1517\/14656566.7.7.907","article-title":"Bexarotene in the treatment of cutaneous T-cell lymphoma","volume":"7","author":"Querfeld","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"B131","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaad.2003.11.058","article-title":"Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma","volume":"51","author":"Querfeld","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.1038\/s41388-018-0126-2","article-title":"Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer","volume":"37","author":"Reebye","year":"2018","journal-title":"Oncogene"},{"key":"B133","doi-asserted-by":"crossref","DOI":"10.1007\/978-90-481-9531-2","volume-title":"From Molecular to Modular Tumor Therapy: Tumors are Reconstructible Communicatively Evolving Systems","author":"Reichle","year":"2010"},{"key":"B134","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-007-6866-6","volume-title":"Evolution-Adjusted Tumor Pathophysiology","author":"Reichle","year":"2013"},{"key":"B135","first-page":"87","article-title":"C-reactive protein in patients with metastatic clear cell renal carcinoma: an important biomarker for tumor-associated inflammation","volume":"1","author":"Reichle","year":"","journal-title":"Biomark. Insights"},{"key":"B136","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1182\/blood.V120.21.5029.5029","article-title":"Anti-Inflammatory, immuno-modulatory and angiostatic treatment as third-line therapy for multiple myeloma (MM) - a combined treatment setting of lenalidomide with pioglitazone, dexamethasone and low-dose treosulfan (phase I\/II)","volume":"120","author":"Reichle","year":"2012","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12307-009-0023-x","article-title":"Principles of modular tumor therapy","volume":"2","author":"Reichle","year":"2009","journal-title":"Cancer Microenviron."},{"key":"B138","doi-asserted-by":"publisher","first-page":"15S","DOI":"10.1200\/jco.2009.27.15s.e15584","article-title":"Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer","volume":"27","author":"Reichle","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s12307-008-0012-5","article-title":"Systems biology: a therapeutic target for tumor therapy","volume":"1","author":"Reichle","year":"2008","journal-title":"Cancer Microenviron."},{"key":"B140","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/CMR.0b013e3282f1d2c8","article-title":"Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial","volume":"17","author":"Reichle","year":"","journal-title":"Melanoma Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1365-2141.2004.05359.x","article-title":"Anti-inflammatory and angiostatic therapy in chemorefractory multisystem Langerhans' cell histiocytosis of adults","volume":"128","author":"Reichle","year":"2005","journal-title":"Br. J. Haematol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1158\/1078-0432.CCR-12-3847","article-title":"Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin","volume":"19","author":"Remark","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B143","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"New Engl. J. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s12885-016-2823-y","article-title":"SAKK 24\/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial","volume":"16","author":"Rochlitz","year":"2016","journal-title":"BMC Cancer"},{"key":"B145","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10637-016-0408-x","article-title":"Current achievements and future perspectives of metronomic chemotherapy","volume":"35","author":"Romiti","year":"2017","journal-title":"Invest. New Drugs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41467-017-00661-x","article-title":"Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1","volume":"8","author":"Rosner","year":"2017","journal-title":"Nat. Commun."},{"key":"B147","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2018.01.020","article-title":"Anti-leukemic effects of PPAR\u03b3 ligands","volume":"418","author":"Ryu","year":"2018","journal-title":"Cancer Lett."},{"key":"B150","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.molmet.2018.05.013","article-title":"PPAR\u03b3 is dispensable for clear cell renal cell carcinoma progression","volume":"14","author":"Sanchez","year":"2018","journal-title":"Mol. Metab"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2018.36.15_suppl.2509","article-title":"Preliminary results of a first-in-human, first-in-class phase I study of MTL-CEBPA, a small activating RNA (saRNA) targeting the transcription factor C\/EBP-\u03b1 in patients with advanced liver cancer","volume":"36","author":"Sarker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1210\/jcem-70-4-1055","article-title":"Bone mass reduction after estrogen deprivation by long-acting gonadotropin-releasing hormone agonists and its relation to pretreatment serum concentrations of 1,25-dihydroxyvitamin D3","volume":"70","author":"Scharla","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1097\/01.ju.0000140875.07255.f5","article-title":"Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma","volume":"172","author":"Sciarra","year":"2004","journal-title":"J. Urol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/cncr.30411","article-title":"Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high-grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment","volume":"123","author":"Senerchia","year":"2017","journal-title":"Cancer"},{"key":"B156","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.trecan.2017.03.006","article-title":"Super-enhancer-driven transcriptional dependencies in cancer","volume":"3","author":"Sengupta","year":"2017","journal-title":"Trends Cancer"},{"key":"B157","doi-asserted-by":"publisher","first-page":"CD004562","DOI":"10.1002\/14651858.CD004562.pub3","article-title":"LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women","author":"Sharma","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"B158","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1634\/theoncologist.2011-0458","article-title":"Antitumor effects of somatostatin analogs in neuroendocrine tumors","volume":"17","author":"Sid\u00e9ris","year":"2012","journal-title":"Oncologist"},{"key":"B159","doi-asserted-by":"publisher","first-page":"e0174761","DOI":"10.1371\/journal.pone.0174761","article-title":"Regulation of white and brown adipocyte differentiation by RhoGAP DLC1","volume":"12","author":"Sim","year":"2017","journal-title":"PLoS ONE"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"B161","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-\u03b12b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.20493","article-title":"Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and\/or radiation therapy","volume":"101","author":"Smith","year":"2004","journal-title":"Cancer"},{"key":"B163","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1016\/j.jaad.2007.07.012","article-title":"Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate","volume":"58","author":"Steinhoff","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10549-011-1593-0","article-title":"Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer","volume":"128","author":"Sverrisdottir","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B165","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5306\/wjco.v8.i3.241","article-title":"Current state and controversies in fertility preservation in women with breast cancer","volume":"8","author":"Taylan","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"932632","DOI":"10.1155\/2008\/932632","article-title":"PPARgamma, PTEN, and the fight against cancer","volume":"2008","author":"Teresi","year":"2008","journal-title":"PPAR Res."},{"key":"B167","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1054\/bjoc.2000.1669","article-title":"Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer","volume":"84","author":"Thirion","year":"2001","journal-title":"Br. J. Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.3324\/haematol.2014.115055","article-title":"Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia","volume":"100","author":"Thomas","year":"2015","journal-title":"Haematologica"},{"key":"B169","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/10428199909083393","article-title":"High dose methyl prednisolone in refractory chronic lymphocytic leukaemia","volume":"34","author":"Thornton","year":"1999","journal-title":"Leuk. Lymphoma"},{"key":"B170","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1158\/1535-7163.MCT-15-0724","article-title":"Dual targeting of bromodomain and extraterminal domain proteins, and WNT or MAPK signaling, inhibits c-MYC expression and proliferation of colorectal cancer cells","volume":"15","author":"T\u00f6gel","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"B171","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1073\/pnas.94.1.237","article-title":"Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor","volume":"94","author":"Tontonoz","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B172","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1196\/annals.1386.018","article-title":"From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion","volume":"1089","author":"Trosko","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B173","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-07-5185","article-title":"A phase I study of bexarotene, a retinoic X receptor agonist, in non-M acute myeloid leukemia","volume":"14","author":"Tsai","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B174","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bjh.13480","article-title":"Biomodulatory metronomic therapy induces PET-negative remission in chemo- and brentuximab-refractory Hodgkin lymphoma","volume":"172","author":"Ugocsai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3389\/fimmu.2018.00745","article-title":"Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT\/\u03b2-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis","volume":"9","author":"Vall\u00e9e","year":"2018","journal-title":"Front. Immunol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12264-018-0219-5","article-title":"Opposite interplay between the canonical WNT\/\u03b2-catenin pathway and PPAR gamma: a potential therapeutic target in gliomas","volume":"34","author":"Vall\u00e9e","year":"2018","journal-title":"Neurosci. Bull."},{"key":"B177","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","article-title":"Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma","volume":"35","author":"van Beurden-Tan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3332\/ecancer.2015.513","article-title":"Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent","volume":"9","author":"van Nuffel","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"B179","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"B180","volume-title":"Die Cellularpathologie in Ihrer Begr\u00fcndung auf Physiologische und Pathologische Gewebelehre","author":"Virchow","year":"1859"},{"key":"B181","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12307-014-0161-7","article-title":"Biomodulatory treatment of patients with castration-resistant prostate cancer: a phase ii study of imatinib with pioglitazone, etoricoxib, dexamethasone and low-dose treosulfan","volume":"8","author":"Vogelhuber","year":"2015","journal-title":"Cancer Microenviron."},{"key":"B182","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(06)70798-7","article-title":"Antiangiogenic therapy in metastatic prostate carcinoma complicated by cutaneous lupus erythematodes","volume":"7","author":"Vogt","year":"2006","journal-title":"Lancet Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1002\/cncr.11775","article-title":"Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors","volume":"98","author":"Vogt","year":"2003","journal-title":"Cancer"},{"key":"B184","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s00345-010-0567-x","article-title":"Modular therapy approach in metastatic castration-refractory prostate cancer","volume":"28","author":"Walter","year":"2010","journal-title":"World J. Urol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12032-011-9982-0","article-title":"Pioglitazone, etoricoxib, interferon-\u03b1, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial","volume":"29","author":"Walter","year":"2012","journal-title":"Med. Oncol."},{"key":"B186","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12032-017-1040-0","article-title":"Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial","volume":"34","author":"Walter","year":"2017","journal-title":"Med. Oncol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00280-012-1828-8","article-title":"The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/15384047.2017.1385675","article-title":"Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features","volume":"19","author":"Was","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"B189","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"New Engl. J. Med."},{"key":"B190","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","article-title":"Master transcription factors and mediator establish super-enhancers at key cell identity genes","volume":"153","author":"Whyte","year":"2013","journal-title":"Cell"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","article-title":"DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation","volume":"348","author":"Winter","year":"2015","journal-title":"Science"},{"key":"B192","doi-asserted-by":"publisher","first-page":"6727421","DOI":"10.1155\/2018\/6727421","article-title":"Peroxisome proliferator-activated receptor \u03b3 and PGC-1\u03b1 in cancer: dual actions as tumor promoter and suppressor","volume":"2018","author":"Yun","year":"2018","journal-title":"PPAR Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000336483","article-title":"Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience","volume":"82","author":"Zapletalova","year":"2012","journal-title":"Oncology"},{"key":"B194","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/1574888X10666150728122921","article-title":"Expression and function of PPARs in cancer stem cells","volume":"11","author":"Zhang","year":"2016","journal-title":"Curr. Stem Cell Res. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01357\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T04:52:10Z","timestamp":1573015930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01357\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,28]]},"references-count":194,"alternative-id":["10.3389\/fphar.2018.01357"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01357","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,28]]},"article-number":"1357"}}